Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...

Eupraxia Pharmaceuticals (EPRX)announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic ...

Eupraxia Pharmaceuticals (TSE:EPRX) has released an update. Eupraxia Pharmaceuticals has announced promising results from their RESOLVE trial ...

Medically reviewed by Qin Rao, MD Endoscopy procedures for the digestive system—upper endoscopy and colonoscopy—are similar ...

3Q Loss C$2.66M D-Box Technologies 3Q Rev C$12.1M Discovery Silver 3Q Loss/Shr C$0.01 Eupraxia Pharmaceuticals Announces Positive Data From Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for ...

The Western medical establishment ousted him. China embraced him. Will the man on a mission to perform the first human head transplant ever pull it off?

Receiving an accurate diagnosis of Crohn’s disease and starting treatment right away is important to avoid ... and a camera ...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the third quarter 2024 and provided a business update. "The Mirum team executed ...

Reflects impairment of the goodwill and intangible assets recognized as a result of Illumina's acquisition of the Company in August 2021 ("the Acquisition"). GrowGeneration Corp. ("GrowGeneration," ...